

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM589729

SUBMISSION TYPE:	RESUBMISSION
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST
RESUBMIT DOCUMENT ID:	900545430

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
TC Lending, LLC, as collateral agent		04/13/2020	Limited Liability Company: DELAWARE

RECEIVING PARTY DATA

Name:	Nektar Therapeutics
Street Address:	455 Mission Bay Blvd South
City:	San Francisco
State/Country:	CALIFORNIA
Postal Code:	94158
Entity Type:	Corporation: DELAWARE

PROPERTY NUMBERS Total: 8

Property Type	Number	Word Mark
Serial Number:	86147364	INVEEOX
Serial Number:	85724646	IT'S ABOUT TIME
Serial Number:	78157780	NEKTAR
Serial Number:	78157784	NEKTAR
Serial Number:	85592487	NEKTAR
Serial Number:	77978284	NEKTAR
Serial Number:	86433872	ONZEALD
Serial Number:	86571263	TEPTOLZA

CORRESPONDENCE DATA

Fax Number: 4088156555

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4152734319

Email: tmadmin@kilpatricktownsend.com

Correspondent Name: Jennifer D. Arkowitz

Address Line 1: 1100 Peachtree Street, Suite 2800

Address Line 2: Mailstop: IP Docketing - 22

Address Line 4: Atlanta, GEORGIA 30309

ATTORNEY DOCKET NUMBER:	0543814
NAME OF SUBMITTER:	Amy Wells
SIGNATURE:	/Amy M. Wells/
DATE SIGNED:	07/31/2020

Total Attachments: 7

source=Termination and Release of Grant of Security Interest in United States Trademarks - Nektar 256160292#page1.tif

source=Termination and Release of Grant of Security Interest in United States Trademarks - Nektar 256160292#page2.tif

source=Termination and Release of Grant of Security Interest in United States Trademarks - Nektar 256160292#page3.tif

source=Termination and Release of Grant of Security Interest in United States Trademarks - Nektar 256160292#page4.tif

source=Termination and Release of Grant of Security Interest in United States Trademarks - Nektar 256160292#page5.tif

source=Termination and Release of Grant of Security Interest in United States Trademarks - Nektar 256160292#page6.tif

source=Assignment Notice of Non-Recordation#page2.tif

TERMINATION AND RELEASE OF
GRANT OF SECURITY INTEREST IN UNITED STATES TRADEMARKS

This TERMINATION AND RELEASE OF GRANT OF SECURITY INTEREST IN UNITED STATES TRADEMARKS (“Termination and Release”) dated as of April 13, 2020, is made by TC LENDING, LLC, as collateral agent (the “Collateral Agent”) in favor of NEKTAR THERAPEUTICS, a Delaware corporation (the “Grantor”). Capitalized terms used in this Termination and Release and not otherwise defined herein have the meanings specified in the Pledge and Security Agreement (as defined below) or the Trademark Security Agreement (as defined below), as applicable.

WITNESSETH:

WHEREAS, pursuant to that certain Pledge and Security Agreement dated as of October 5, 2015 (as amended, modified, restated and/or supplemented from time to time the “Pledge and Security Agreement”), the Grantor executed a Grant of Security Interest in United States Trademarks dated as of October 5, 2015 (the “Trademark Security Agreement”), between the Grantor and the Collateral Agent, recorded with the United States Patent and Trademark Office on October 6, 2015 at Reel 5639, Frame 149, pursuant to which the Grantor granted to the Collateral Agent, among other collateral as set forth therein, a continuing security interest in all of the Grantor’s right, title and interest in, to and under the trademarks and/or trademark applications listed on Schedule A hereto and made a part hereof (the “Trademarks”).

WHEREAS, the Collateral Agent now desires to terminate the Trademark Security Agreement and terminate and release its security interest in the Trademarks and reassign any and all rights, title, and interest in the same to Grantor.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

1. Collateral Agent hereby irrevocably terminates the Trademark Security Agreement and irrevocably discharges, terminates and releases its lien on and security interest in all of Grantor’s right, title and interest in and to the Trademarks.

2. Collateral Agent hereby assigns, grants and conveys to the Grantor, without any representation, warranty, recourse or undertaking by the Collateral Agent, any and all of Collateral Agent’s right, title, and interest in and to the Trademarks.

3. The Collateral Agent authorizes and requests that the Commissioner of the United States Patent and Trademark Office and any other applicable government authority record this Termination and Release.

4. This Termination and Release and the rights and obligations of the parties hereto shall be governed by and construed and interpreted in accordance with the laws of the State of

New York and shall be binding upon the parties' representatives, successors, assigns and transferees.

[signature page follows]

IN WITNESS WHEREOF, the undersigned has caused this Termination and Release to be duly executed and delivered by its officer thereunto duly authorized as of the date first written above.

TC LENDING, LLC,
as Collateral Agent



By: _____
Name: Robert (Bo) Stanley
Title: President

[Termination and Release of
Grant of Security Interest in United States Trademarks]

TRADEMARK
REEL: 007005 FRAME: 0960

SCHEDULE A
TO
TERMINATION AND RELEASE OF
GRANT OF SECURITY INTEREST IN UNITED STATES TRADEMARKS

[See Attached]

Nektar Therapeutics
Trademarks

Jurisdiction	Mark	Status	Serial No Filing Date	Reg. No. Reg. Date	Owner	Class/Description
United States	INVEEOK	Allowed	26147364 Dec 18, 2013		Nektar Therapeutics	05 Pharmaceutical preparations, namely, an anti-cancer agent.
United States	IT'S ABOUT TIME	Allowed	25724646 Sep 10, 2012		Nektar Therapeutics	05 Pharmaceuticals, namely, pharmaceutical preparations having enhanced drug performance for the treatment and prophylaxis of pain and of nerve diseases
United States	NEKTAR	Registered	78157780 Aug 26, 2002	2069869 Mar 14, 2006	Nektar Therapeutics	05 Pharmaceutical, namely, pharmaceutical preparations having enhanced drug performance and/or drug delivery performance for the treatment and/or prophylaxis of diseases or medical conditions such as diabetes, infections, cancers, and inflammations, or of diseases or medical conditions that affect the peripheral nerves, the adrenergic and/or cholinergic receptors, the histamine receptors, the expression and/or regulation of growth factors, the skeletal and/or smooth muscle systems, the cardiovascular system, the endocrine and/or hormone systems, the blood circulatory system, the immunological system, the synaptic and neuroeffector junctional sites, the reproductive system, the skeletal system, the autonomic system, the alimentary and/or excretory systems, and/or the central nervous system.
United States	NEKTAR	Registered	78157784 Aug 26, 2002	2321731 Mar 9, 2004	Nektar Therapeutics	42 Research services, namely, providing research and development services for others in the biotechnical, biomedical and pharmaceutical fields.

Nektar Therapeutics
Trademarks

Jurisdiction	Mark	Status	Serial No Filing Date	Reg. No. Reg. Date	Owner	Class/Description
United States	NEKTAR (Stylized) NEKTAR	Allowed	85592487 Apr 9, 2012		Nektar Therapeutics	05 Pharmaceuticals, namely, pharmaceutical preparations having enhanced drug performance for the treatment of medical conditions in the nature of cancer; pharmaceuticals, namely, pharmaceutical preparations having enhanced drug performance for the treatment of medical conditions affecting peripheral nerves and peripheral nerve pain; pharmaceuticals, namely, pharmaceutical preparations having enhanced drug performance for the treatment of medical conditions affecting the central nervous system and pain in the central nervous system.
United States	NEKTAR (Stylized) NEKTAR	Registered	77978284 Jun 30, 2008	3735282 Jan 5, 2010	Nektar Therapeutics	42 Research services, namely, providing research and development services for others in the biotechnical, biomedical and pharmaceutical fields.
United States	ONZEALD	Allowed	86433872 Oct 24, 2014		Nektar Therapeutics	05 Pharmaceutical preparations, namely an anti-cancer agent.
United States	TEPTOLZA	Published	86571263 Mar 20, 2015		Nektar Therapeutics	05 Pharmaceutical preparations, namely, an anti-cancer agent.

TRADEMARK

REEL: 007005 FRAME: 0963